Search Results
Jan 19, 2026, 02:00 ET Henlius presenta su estrategia "Globalización 2.0" y su plan de innovación a medio y largo plazo en JPM 2026
HLX22, un nuevo mAb anti-HER2 de epítopo; HLX43, un ADC PD-L1; y HLX07, un mAb anti-EGFR.Actualmente, la cartera de activos preclínicos de la Compañía abarca múltiples modalidades moleculares, incluyendo anticuerpos, TCE multiespecíficos, ADC, proteínas de fusión y moléculas pequeñas, con un enfoque
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius présente sa stratégie « Globalisation 2.0 » et son plan d'innovation à moyen et long terme lors de la conférence JPM 2026
anti-HER2 à nouvel épitope ; le HLX43, un ADC PD-L1 ; et le HLX07, un AcM anti-EGFR.Actuellement, le portefeuille d'actifs précliniques de la société couvre de multiples modalités moléculaires, y compris les anticorps, les TCE multispécifiques, les ADC, les protéines de fusion et les petites molécules,
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius präsentiert auf der JPM 2026 die Strategie „Globalisation 2.0" sowie einen mittel- bis langfristigen Innovationsfahrplan
Jahr 2026 vor, darunter Serplulimab (Handelsname: Hetronifly® in Europa), ein Anti-PD-1-MAb; HLX22, ein neuartiger Epitop-Anti-HER2-MAb; HLX43, ein PD-L1-ADC; und HLX07, ein Anti-EGFR-MAb.Derzeit umfasst das präklinische Portfolio des Unternehmens mehrere molekulare Modalitäten, darunter Antikörper,
More news about: Henlius
Jan 16, 2026, 18:22 ET 2026 China FIC Innovation and Collaboration Summit Held in San Francisco, Chinese Pharmaceutical Companies Showcase Innovative Achievements
antibody–drug conjugate (ADC) technology platform. Featuring a highly hydrophilic linker–payload structure in molecular design, the platform is expected to enhance drug stability, prolong in vivo half-life, and reduce the risk of non-specific clearance, offering a new technological pathway for ADC drug development.During
More news about: Beijing Hotgen Biotech Co., Ltd.
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
EGFR ADC developed on the Hanjugator™ ADC platform, designed to maximize antibody function while delivering a stronger bystander effect, for the treatment of NSCLC and colorectal cancer.HLX49: Potential BIC HER2xHER2 novel bi-paratopic ADC developed on the Hanjugator™ ADC platform,
More news about: Henlius
Jan 16, 2026, 07:30 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
innovation assets in 2026, including serplulimab (trade name: Hetronifly® in Europe), an anti-PD-1 mAb; HLX22, a novel epitope anti-HER2 mAb; HLX43, a PD-L1 ADC; and HLX07, an anti-EGFR mAb.At present, the Company's preclinical asset portfolio spans multiple molecular modalities, including antibodies,
More news about: Henlius
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
TCEsATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO+ADC " dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of immuno-oncology (IO) therapies.
More news about: Antengene Corporation Limited
Jan 15, 2026, 19:00 ET JPM 2026 | 科倫博泰CEO葛均友博士全面展示公司創新成果及未來發展戰略
年創新啟程以來，科倫博泰已快速成長為中國創新藥領域的領導者，構建了差異化的技術平台與研發管線。依託全球領先的抗體偶聯藥物（ADC）及新型偶聯藥物（DC）技術平台 OptiDC™，公司持續推進 ADC 及新型 DC 的差異化開發，形成了治療多瘤種的梯度式管線布局。目前，科倫博泰已有蘆康沙妥珠單抗（sac-TMT，佳泰萊®）與博度曲妥珠單抗（舒泰萊®）兩款 ADC 藥物上市，覆蓋乳腺癌及肺癌兩大適應症；另有 9 款經獨特設計的 ADC 及新型 DC 藥物處於臨床階段，涵蓋雙特異性 ADC、放射性核素偶聯藥物（RDC）等前沿方向。面向乳腺癌、肺癌、消化道腫瘤這些國內高發瘤種，公司已啟動 9 項關鍵性研究，同時針對婦科腫瘤的多項 II 期臨床研究也在穩步推進。此外，公司亦布局了多個非
More news about: 科倫博泰
Jan 15, 2026, 13:30 ET Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
has two ADC products on market: sacituzumab tirumotecan (sac-TMT, 佳泰莱®) and trastuzumab botidotin (舒泰莱®), covering breast cancer and lung cancer indications. Additionally, nine uniquely designed ADC and novel DC drugs—including cutting-edge directions such as bispecific ADC and radiopharmaceutical
More news about: Kelun-Biotech
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jan 15, 2026, 09:00 ET US Army Awards Appian Enterprise Agreement to Support AI-Powered Transformation Efforts
Cloud (ADC) is now Authorized to Operate (Conditionally) (ATO-C) by the Army, further supporting their push for faster adoption of secure commercial technologies. ADC brings commercial parity to an IL5 environment, ensuring warfighters always have access to the latest AI technology. The ADC Army
More news about: Appian
Jan 14, 2026, 23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
areas—bispecific/multispecific antibodies, ADCs, and mAbs—leveraging its deep expertise and fully integrated end-to-end capabilities.Bispecific/multispecific antibody and ADC projects continued to expand rapidly, with each growing by approximately 30% to reach 196 and 252 projects, respectively.
More news about: WuXi Biologics
Jan 14, 2026, 10:00 ET Fibocom Launches Global LTE Cat.1 bis Module LE271-GL
supports LBS + Wi-Fi scan positioning (for indoor and international use), eSIM, and single/dual-SIM configurations. It integrates USB, UART, SPI, I2C, ADC, LCD, Camera, and GPIO interfaces, and supports TTS, MQTT, HTTP, and SSL protocols for versatile IoT applications.Now in the engineering sample
More news about: Fibocom Wireless Inc.
Jan 13, 2026, 20:18 ET Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
by 2030 and 41 products by 2038.The company's ADC candidates are designed to target solid tumor cancers; with IND applications for CT-P70, CT-P71 and CT-P73 accepted by the U.S. Food and Drug Administration (FDA) in 2025. CT-P70, a novel ADC candidate being developed for the treatment of non-small
More news about: Celltrion
Jan 13, 2026, 18:46 ET Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
antibody intermediates and their conjugates for Rakuten Medical's programs, through its specialized ADC manufacturing facility at the Syracuse Bio Campus in New York. The facility is equipped with dedicated ADC production capabilities and advanced bioconjugation technologies, enabling the company to deliver
More news about: LOTTE BIOLOGICS
Jan 13, 2026, 18:00 ET Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
antibody intermediates and their conjugates for Rakuten Medical's programs, through its specialized ADC manufacturing facility at the Syracuse Bio Campus in New York. The facility is equipped with dedicated ADC production capabilities and advanced bioconjugation technologies, enabling the company to deliver
More news about: Rakuten Medical, Inc.
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
and cemiplimab.Initiated novel subcutaneous dosing with BHV-1510, first and only Trop2 ADC in clinic with potential subcutaneous route of administration.First-in-class FGFR3 directed ADC, BHV-1530, continues with dose escalation and no dose limiting toxicities to date.Advancements
More news about: Biohaven Ltd.
Jan 12, 2026, 08:30 ET Operationalizing ADC Clinical Trials: Best Practices for Success, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into the antibody-drug conjugate (ADC) therapeutic landscape and pipeline. Attendees will be introduced to global site selection, preparedness and training required for successful ADC development. The featured speakers will discuss dose optimization and safety
More news about: Xtalks
Jan 12, 2026, 07:30 ET AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
tumor microenvironment for antibody-drug conjugate (ADC) activity, PD-1/VEGF bispecific antibodies are also being explored in combination with ADCs. In early clinical studies, RC148 has shown initial favorable antitumor activity in combination with an ADC.RC148 further strengthens AbbVie's diverse
More news about: AbbVie
Jan 11, 2026, 12:00 ET IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
Administration (FDA) and/or NCCN/compendia listing in this patient subsetAntibody-drug Conjugate (ADC) + DNA damage response (DDR) combinationsIDE849 (DLL3 TOP1 ADC): target to initiate a monotherapy registrational study in the second line/refractory setting (2L+) of small
More news about: IDEAYA Biosciences, Inc.
Jan 08, 2026, 19:00 ET MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types. Under the terms of the agreement, MediLink will grant Roche an exclusive license to develop,
More news about: MediLink Therapeutics
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
for PSMA-targeting ADC. IND-enabling activities for the Company's exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC were completed at the end of 2025. The Company continues to explore partnership opportunities.About ADC TherapeuticsADC Therapeutics (NYSE:
More news about: ADC Therapeutics SA
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jan 08, 2026, 08:00 ET Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
MUC16-targeted ADC, to the FDA in December 2025. A Phase 1 trial is anticipated to start recruiting this quarter and is expected to initially evaluate activity in two high MUC16-expressing gynecologic cancers, ovarian and endometrial.Both next-generation ADC programs leverage Whitehawk's advanced ADC technology
More news about: Whitehawk Therapeutics, Inc.
Jan 08, 2026, 07:15 ET ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA